Brainstorm Cell Therapeutics Secures $1M Private Placement Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Source: seekingalpha
- Financing Agreement: Brainstorm Cell Therapeutics has entered into a definitive agreement for a $1M private placement, with common stock priced at $0.60 per share, representing a significant premium over the $0.54 closing price on February 9, 2026, indicating strong market confidence in the company's future prospects.
- Payment Structure: The financing is structured in two tranches, with the first $500,000 already received and the second $500,000 expected within 30 days, allowing the company to alleviate short-term funding pressures while supporting its R&D activities.
- Clinical Trial Support: Proceeds from the financing will be allocated to support the upcoming Phase 3b trial of the ALS treatment NurOwn and related regulatory initiatives, demonstrating the company's commitment to accelerating market access for its key product.
- Investment Terms Advantage: The investment includes 120% warrant coverage with an exercise price of $1.00 per share, enhancing potential returns for investors while providing the company with additional financial flexibility to address future capital needs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
